(R)-N-(3-methylbutan-2-yl)-5-(pyridin-2-ylethynyl)picolinamide | 1428631-27-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (R)-N-(3-methylbutan-2-yl)-5-(pyridin-2-ylethynyl)picolinamide
• 英文别名: N-[(2R)-3-methylbutan-2-yl]-5-(2-pyridin-2-ylethynyl)pyridine-2-carboxamide
• CAS: 1428631-27-9
• 化学式: C₁₈H₁₉N₃O
• 分子量: 293.368
• InChiKey: QRAJYRQWZBIRRW-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-溴-2-吡啶羧酸 、 (R)-(-)-3-甲基-2-丁胺 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 二乙胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.92h， 生成 (R)-N-(3-methylbutan-2-yl)-5-(pyridin-2-ylethynyl)picolinamide
  参考文献：
  名称：

  Exploration of Allosteric Agonism Structure–Activity Relationships within an Acetylene Series of Metabotropic Glutamate Receptor 5 (mGlu₅) Positive Allosteric Modulators (PAMs): Discovery of 5-((3-Fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254)

  摘要：

  Positive allosteric modulators (PAMs) of metabotropic glutamate receptor 5 (mGlu(5)) represent a promising therapeutic strategy for the treatment of schizophrenia. Both allosteric agonism and high glutamate fold-shift have been implicated in the neurotoxic profile of some mGlu(5) PAMs; however, these hypotheses remain to be adequately addressed. To develop tool compounds to probe these hypotheses, the structure-activity relationship of allosteric agonism was examined within an acetylenic series of mGlu(5) PAMs exhibiting allosteric agonism in addition to positive allosteric modulation (ago-PAMs). PAM 38t, a low glutamate fold-shift allosteric ligand (maximum fold-shift similar to 3.0), was selected as a potent PAM with no agonism in the in vitro system used for compound characterization and in two native electrophysiological systems using rat hippocampal slices. PAM 38t (ML254) will be useful to probe the relative contribution of cooperativity and allosteric agonism to the adverse effect liability and neurotoxicity associated with this class of mGlu(5) PAMs.

  DOI：

  10.1021/jm401028t

文献信息

• [EN] SUBSTITUED 5-(PROP-1-YN-1-YL)PICOLINAMIDE ANALOGS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS<br/>[FR] ANALOGUES DE 5-(PROP-1-YN-1-YL)PICOLINAMIDE SUBSTITUÉ COMME MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS DE MGLUR5
  申请人：UNIV VANDERBILT

  公开号：WO2013049255A1

  公开（公告）日：2013-04-04

  In one aspect, the invention relates to substituted 5-(prop-1-yn-1-yl)picolinamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，该发明涉及替代的5-(丙炔基)吡啶甲酰胺类似物，其衍生物和相关化合物，这些化合物可用作代谢型谷氨酸受体亚型5(mGluR5)的阳性变构调节剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与谷氨酸功能异常相关的神经和精神疾病的方法。本摘要旨在作为在特定领域进行搜索的扫描工具，并不打算限制本发明。
• Exploration of Allosteric Agonism Structure–Activity Relationships within an Acetylene Series of Metabotropic Glutamate Receptor 5 (mGlu₅) Positive Allosteric Modulators (PAMs): Discovery of 5-((3-Fluorophenyl)ethynyl)-<i>N</i>-(3-methyloxetan-3-yl)picolinamide (ML254)
  作者：Mark Turlington、Meredith J. Noetzel、Aspen Chun、Ya Zhou、Rocco D. Gogliotti、Elizabeth D. Nguyen、Karen J. Gregory、Paige N. Vinson、Jerri M. Rook、Kiran K. Gogi、Zixiu Xiang、Thomas M. Bridges、J. Scott Daniels、Carrie Jones、Colleen M. Niswender、Jens Meiler、P. Jeffrey Conn、Craig W. Lindsley、Shaun R. Stauffer

  DOI：10.1021/jm401028t

  日期：2013.10.24

  Positive allosteric modulators (PAMs) of metabotropic glutamate receptor 5 (mGlu(5)) represent a promising therapeutic strategy for the treatment of schizophrenia. Both allosteric agonism and high glutamate fold-shift have been implicated in the neurotoxic profile of some mGlu(5) PAMs; however, these hypotheses remain to be adequately addressed. To develop tool compounds to probe these hypotheses, the structure-activity relationship of allosteric agonism was examined within an acetylenic series of mGlu(5) PAMs exhibiting allosteric agonism in addition to positive allosteric modulation (ago-PAMs). PAM 38t, a low glutamate fold-shift allosteric ligand (maximum fold-shift similar to 3.0), was selected as a potent PAM with no agonism in the in vitro system used for compound characterization and in two native electrophysiological systems using rat hippocampal slices. PAM 38t (ML254) will be useful to probe the relative contribution of cooperativity and allosteric agonism to the adverse effect liability and neurotoxicity associated with this class of mGlu(5) PAMs.